Advertisement

ADVERTISEMENT

Jordan Kadish

Conference Coverage
Ibrutinib With and Following AutoHCT Well-Tolerated Among Patients With R/R Activated-B-Cell Subtype DLBCL
12/10/2023
The addition of ibrutinib with and following autoHCT showed tolerability and may improve progression-free survival among patients with relapsed/refractory activated B-cell subtype diffuse large B-cell lymphoma, according to a primary analysis...
The addition of ibrutinib with and following autoHCT showed tolerability and may improve progression-free survival among patients with relapsed/refractory activated B-cell subtype diffuse large B-cell lymphoma, according to a primary analysis...
The addition of ibrutinib with...
12/10/2023
Oncology
News
Exclusion of Involved-Node Radiotherapy Among ePET-Negative Vs ePET-Positive Patients With Localized Hodgkin Lymphoma
01/17/2024
A 10-year trial follow-up indicated that the exclusion of involved-node radiotherapy was correlated with lower progression-free survival among ePET-negative patients with localized Hodgkin lymphoma.
A 10-year trial follow-up indicated that the exclusion of involved-node radiotherapy was correlated with lower progression-free survival among ePET-negative patients with localized Hodgkin lymphoma.
A 10-year trial follow-up...
01/17/2024
Oncology
News
Polatuzumab Vedotin Plus R-CHOP Improved PFS Among Patients With DLBCL
03/22/2023
According to the phase 3 POLARIX trial, polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHOP) improved progression-free survival among patients with previously untreated diffuse large b-cell lymphoma.
According to the phase 3 POLARIX trial, polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHOP) improved progression-free survival among patients with previously untreated diffuse large b-cell lymphoma.
According to the phase 3 POLARIX...
03/22/2023
Oncology
News
Odronextamab Demonstrated High Complete Response Rates in Patients With R/R Follicular Lymphoma
02/15/2023
A pivotal phase 2 study found that the implementation of odronextamab for patients with relapsed/refractory follicular lymphoma grade 1 to 3a resulted in high complete response rates.
A pivotal phase 2 study found that the implementation of odronextamab for patients with relapsed/refractory follicular lymphoma grade 1 to 3a resulted in high complete response rates.
A pivotal phase 2 study found...
02/15/2023
Oncology
News
FDA Grants Accelerated Approval to Glofitamab for Patients With R/R Diffuse Large B-Cell Lymphoma
06/23/2023
On June 15, 2023, the FDA granted accelerated approval to glofitamab-gxbm for the treatment of patients with relapsed/refractory DLBCL, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after ≥ 2 lines of...
On June 15, 2023, the FDA granted accelerated approval to glofitamab-gxbm for the treatment of patients with relapsed/refractory DLBCL, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after ≥ 2 lines of...
On June 15, 2023, the FDA...
06/23/2023
Oncology
News
Combination of CCAG Regimen and Donor Lymphocyte Infusion Induced Durable Remission and Superior Survival Among Patients With Relapsed AML/MDS
02/27/2023
A single-arm phase 2 study found that a combination of chidamine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor followed by donor lymphocyte infusion induced durable remission and superior survival in patients with...
A single-arm phase 2 study found that a combination of chidamine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor followed by donor lymphocyte infusion induced durable remission and superior survival in patients with...
A single-arm phase 2 study found...
02/27/2023
Oncology
News
Fractionated BCMA-Directed CAR T-Cell Therapy ARI0002h Demonstrates Encouraging Responses Among Patients With R/R Multiple Myeloma
10/23/2023
ARI0002h, a BCMA-targeted CAR T-cell therapy, demonstrated encouraging responses when administered in a fractionated manner with a booster dose after 3 months to patients with R/R multiple myeloma, according to an interim analysis of a pilot...
ARI0002h, a BCMA-targeted CAR T-cell therapy, demonstrated encouraging responses when administered in a fractionated manner with a booster dose after 3 months to patients with R/R multiple myeloma, according to an interim analysis of a pilot...
ARI0002h, a BCMA-targeted CAR...
10/23/2023
Oncology
News
PBM Mismatches in Unrelated Donor HCT Associated With Lower Overall Survival and Increased Risk of GVHD
02/28/2023
Peptide-binding motif mismatches were associated with lower overall survival and a higher risk of transplant-related mortality and graft-versus-host disease in HLA-mismatched unrelated donor hematopoietic cell transplantation, according to a...
Peptide-binding motif mismatches were associated with lower overall survival and a higher risk of transplant-related mortality and graft-versus-host disease in HLA-mismatched unrelated donor hematopoietic cell transplantation, according to a...
Peptide-binding motif mismatches...
02/28/2023
Oncology
News
Zanubrutinib Shows Promise for Patients With B-Cell Malignancies Intolerant of Other BTK Inhibitors
04/10/2023
Results of a phase 2 trial indicate that using zanubrutinib as a treatment for b-cell malignancies yielded safe and effective results among patients intolerant of other BTK inhibitors.
Results of a phase 2 trial indicate that using zanubrutinib as a treatment for b-cell malignancies yielded safe and effective results among patients intolerant of other BTK inhibitors.
Results of a phase 2 trial...
04/10/2023
Oncology
News
Obinutuzumab Plus Bendamustine Treatment Active, Adequately-Tolerated Among Patients With R/R CLL
08/31/2023
The phase 2 GABRIELL trial indicated that the combination of obinutuzumab plus bendamustine demonstrated encouraging activity and was adequately tolerated among patients with relapsed/refractory chronic lymphocytic leukemia.
The phase 2 GABRIELL trial indicated that the combination of obinutuzumab plus bendamustine demonstrated encouraging activity and was adequately tolerated among patients with relapsed/refractory chronic lymphocytic leukemia.
The phase 2 GABRIELL trial...
08/31/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
December 9 ⁠–⁠ December 11
AIBD logo
December 9 ⁠–⁠ December 11
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
December 14 ⁠–⁠ December 15
February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use